帕博西尼联合放疗治疗转移性乳腺癌的安全性与疗效
该回顾性研究纳入2015至2018年间16例接受帕博西尼(CDK4/6抑制剂)并因症状性转移灶接受放疗的转移性乳腺癌患者,评估同期或14天内联合治疗的毒性与局部疗效。结果显示疼痛均缓解,可评估影像者未见局部失败,血液学毒性以1级为主,无2级以上皮肤、神经或胃肠道毒性。
要点
- 帕博西尼与放疗间隔中位5天(0-14天)联合,未观察到3级及以上毒性。
- 所有患者疼痛缓解,13例可评估影像者无局部影像学失败。
- 血液学毒性以1级为主,仅2例为2级,且与治疗时序或照射部位无关。
核心结论
- 帕博西尼联合放疗仅出现轻微2级毒性,无3级及以上毒性,提示症状性转移患者可安全接受放疗。
研究设计与样本
- 回顾性综述2015至2018年本机构接受帕博西尼治疗的患者记录,纳入同期或与帕博西尼间隔14天内接受症状性转移灶放疗者,共16例女性。
主要发现
- 16例中帕博西尼在放疗前、同期、放疗后使用分别为4例(25.0%)、5例(31.3%)、7例(43.8%),最近用药与放疗中位间隔5天(范围0-14天)。
- 照射部位包括骨(11例中轴骨骼[9例椎体、2例其他];4例骨盆;3例肢体)、脑(4例:3例全脑放疗、1例立体定向放射外科)和纵隔(1例)。
- 中位随访14.7个月、平均17.6个月(范围1.7-38.2个月),所有患者疼痛缓解,13例可评估影像者无局部影像学失败。
- 放疗前白细胞减少4例(25.0%)、中性粒细胞减少5例(31.3%)、血小板减少1例(6.3%);放疗后分别为5例(31.3%)、1例(6.3%)、3例(18.8%)。
- 除2例2级血液学毒性外,其余血液学毒性均为1级;未观察到急性或晚期2级及以上皮肤、神经或胃肠道毒性,毒性结果与疾病部位、帕博西尼-放疗时序或照射部位无关。
关键数值与推荐
- 毒性分级依据常见不良事件评价标准(CTCAE)5.0版。
- 局部疗效通过临床检查及后续计算机断层扫描/磁共振成像评估。
临床怎么用
- 对接受帕博西尼治疗的转移性乳腺癌患者,因症状性转移灶需放疗时可考虑联合,但需监测血液学毒性。
局限性
- 回顾性设计、样本量小(16例),随访时间有限,需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Palbociclib is a selective cyclin-dependent kinase 4/6 inhibitor approved for metastatic ER+/HER2- breast cancer. Preclinical evidence suggests a possible synergistic effect of palbociclib when combined with radiation therapy (RT); however, the toxicity of this pairing is unknown. We report preliminary results on the use of this combination. METHODS AND MATERIALS: Records of patients treated with palbociclib at our institution from 2015 to 2018 were retrospectively reviewed. Patients who received RT for symptomatic metastases concurrently or within 14 days of palbociclib were included. Local treatment effect was assessed by clinical examination and subsequent computed tomography/magnetic resonance imaging. Toxicity was graded based on Common Terminology Criteria for Adverse Events version 5.0. RESULTS: A total of 16 women received palliative RT in close temporal proximity to palbociclib administration. Four patients received palbociclib before RT (25.0%), 5 concurrently (31.3%), and 7 after RT (43.8%). The median interval from closest palbociclib use to RT was 5 days (range, 0-14). The following sites were irradiated in decreasing order of frequency: bone (11 axial skeleton [9 vertebra and 2 other]; 4 pelvis; 3 extremity), brain (4: 3 whole brain RT and 1 stereotactic radiosurgery), and mediastinum (1). The median and mean follow-up time is 14.7 and 17.6 months (range, 1.7-38.2). Pain relief was achieved in all patients. No radiographic local failure was noted in the 13 patients with evaluable follow-up imaging. Leukopenia, neutropenia, and thrombocytopenia were seen in 4 (25.0%), 5 (31.3%), and 1 (6.3%) patient before RT. After RT, 5 (31.3%), 1 (6.3%), and 3 (18.8%) patients were leukopenic, neutropenic, and thrombocytopenic, respectively. All but 2 (grade 2) hematologic toxicities were grade 1. No acute or late grade 2+ cutaneous, neurologic, or gastrointestinal toxicities were noted. Toxicity results did not differ based on disease site, palbociclib-RT temporal association, or irradiated site. CONCLUSIONS: The use of RT in patients receiving palbociclib resulted in minimal grade 2 and no grade 3+ toxicities. This preliminary work suggests that symptomatic patients receiving palbociclib may be safely irradiated.
引用
- Chowdhary M, Sen N, Chowdhary A, et al. Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination. Adv Radiat Oncol. 2019. PMID: 31360799. doi:10.1016/j.adro.2019.03.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。